Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Atorvastatin reduces plasma levels of chemokine (CXCL10) in patients with Crohn's disease.

Grip, Olof LU and Janciauskiene, Sabina LU (2009) In PLoS ONE 4(5).
Abstract
BACKGROUND: In Crohn's disease high tissue expression and serum levels of chemokines and their receptors are known to correlate with disease activity. Because statins can reduce chemokine expression in patients with coronary diseases, we wanted to test whether this can be achieved in patients with Crohn's disease. METHODOLOGY/PRINCIPAL FINDINGS: We investigated plasma levels of chemokines (CCL2, CCL4, CCL11, CCL13, CCL17, CCL22, CCL26, CXCL8, CXCL10) and endothelial cytokines (sP-selectin, sE-selectin, sICAM-3, thrombomodulin) in ten Crohn's disease patients before and after thirteen weeks' daily treatment with 80 mg atorvastatin. Of the 13 substances investigated, only CXCL10 was found to be significantly reduced (by 34%, p = 0.026) in... (More)
BACKGROUND: In Crohn's disease high tissue expression and serum levels of chemokines and their receptors are known to correlate with disease activity. Because statins can reduce chemokine expression in patients with coronary diseases, we wanted to test whether this can be achieved in patients with Crohn's disease. METHODOLOGY/PRINCIPAL FINDINGS: We investigated plasma levels of chemokines (CCL2, CCL4, CCL11, CCL13, CCL17, CCL22, CCL26, CXCL8, CXCL10) and endothelial cytokines (sP-selectin, sE-selectin, sICAM-3, thrombomodulin) in ten Crohn's disease patients before and after thirteen weeks' daily treatment with 80 mg atorvastatin. Of the 13 substances investigated, only CXCL10 was found to be significantly reduced (by 34%, p = 0.026) in all of the treated patients. Levels of CXCL10 correlated with C-reactive protein (r = 0.82, p<0.01). CONCLUSIONS/SIGNIFICANCE: CXCL10 is a ligand for the CXCR3 receptor, the activation of which results in the recruitment of T lymphocytes and the perpetuation of mucosal inflammation. Hence the reduction of plasma CXCL10 levels by atorvastatin may represent a candidate for an approach to the treatment of Crohns disease in the future. TRIAL REGISTRATION: (ClinicalTrials.gov) NCT00454545. (Less)
Please use this url to cite or link to this publication:
author
and
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
PLoS ONE
volume
4
issue
5
article number
e5263
publisher
Public Library of Science (PLoS)
external identifiers
  • wos:000265836900001
  • pmid:19421322
  • scopus:65549131046
  • pmid:19421322
ISSN
1932-6203
DOI
10.1371/journal.pone.0005263
language
English
LU publication?
yes
id
94022236-a047-4bf6-b3d9-767993811463 (old id 1412599)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/19421322?dopt=Abstract
date added to LUP
2016-04-04 09:04:51
date last changed
2025-04-04 14:08:34
@article{94022236-a047-4bf6-b3d9-767993811463,
  abstract     = {{BACKGROUND: In Crohn's disease high tissue expression and serum levels of chemokines and their receptors are known to correlate with disease activity. Because statins can reduce chemokine expression in patients with coronary diseases, we wanted to test whether this can be achieved in patients with Crohn's disease. METHODOLOGY/PRINCIPAL FINDINGS: We investigated plasma levels of chemokines (CCL2, CCL4, CCL11, CCL13, CCL17, CCL22, CCL26, CXCL8, CXCL10) and endothelial cytokines (sP-selectin, sE-selectin, sICAM-3, thrombomodulin) in ten Crohn's disease patients before and after thirteen weeks' daily treatment with 80 mg atorvastatin. Of the 13 substances investigated, only CXCL10 was found to be significantly reduced (by 34%, p = 0.026) in all of the treated patients. Levels of CXCL10 correlated with C-reactive protein (r = 0.82, p&lt;0.01). CONCLUSIONS/SIGNIFICANCE: CXCL10 is a ligand for the CXCR3 receptor, the activation of which results in the recruitment of T lymphocytes and the perpetuation of mucosal inflammation. Hence the reduction of plasma CXCL10 levels by atorvastatin may represent a candidate for an approach to the treatment of Crohns disease in the future. TRIAL REGISTRATION: (ClinicalTrials.gov) NCT00454545.}},
  author       = {{Grip, Olof and Janciauskiene, Sabina}},
  issn         = {{1932-6203}},
  language     = {{eng}},
  number       = {{5}},
  publisher    = {{Public Library of Science (PLoS)}},
  series       = {{PLoS ONE}},
  title        = {{Atorvastatin reduces plasma levels of chemokine (CXCL10) in patients with Crohn's disease.}},
  url          = {{http://dx.doi.org/10.1371/journal.pone.0005263}},
  doi          = {{10.1371/journal.pone.0005263}},
  volume       = {{4}},
  year         = {{2009}},
}